- Active, not recruiting
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
Updated: Aug 27, 2022
MMRF CoMMpass Study
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)
The primary objective of this observational study is to identify the molecular profiles and clinical characteristics that define subsets of myeloma patients during the course of the disease.
Understanding the molecular basis of cancer is a critical step toward devising the most effective treatment of the patient as an individual. The promise of molecular targeted therapeutics and personalized cancer care has been demonstrated in breast and lung cancer and chronic myeloid leukemia. However, similar examples of success in multiple myeloma have not been achieved despite extensive basic research as well as clinical advances. What is well understood is that myeloma is a heterogeneous disease with great genetic and epigenetic complexity.22, 23 Therefore, there remains a critical need to understand myeloma patient biology in the context of current patient care.24 The objective of this longitudinal study is to identify patient subgroups and phenotypes defined by molecular profiling and clinical features. These profiles will enable a better understanding of mechanisms of disease, drug response and patient relapse. Ultimately the study is intended to drive successful drug development and patient care in multiple myeloma.
Sponsor
Multiple Myeloma Research Foundation
MMRF
Collaborators:
Translational Genomics Research Institute
Spectrum Health Hospitals
Van Andel Research Institute
Information provided by (Responsible Party):
Multiple Myeloma Research Foundation
ClinicalTrials.gov Identifier: NCT01454297
A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles
First Posted: October 19, 2011
Click here for details on ClinicalTrials.gov
CoMMpass Study
NCT03657251: MMRF CureCloud Research Initiative
NCT03657251: MMRF CureCloud Research Initiative
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Blood; 2018 Aug
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
Leukemia; 2018 Apr
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
Nat Commun; 2019 Aug
Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study
Clin Lymphoma Myeloma Leuk;2019
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.
Clin Cancer Res. 2021 Jun
Evolution and structure of clinically relevant gene fusions in multiple myeloma.
Nat Commun. 2020
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
Blood Cancer J. 2017
MMRFBiolinks: an R-package for integrating and analyzing MMRF-CoMMpass data
Brief Bioinform; 2021
NIH National Cancer Institute - Genomics Data Commons: The Multiple Myeloma Research Foundation (MMRF)
CoMMpass from the Multiple Myeloma Research Foundation
Registry of Open Data on AWS
OAB-018 From CARDAMON to CoMMpass: A mutational signature that predicts carfilzomib-specific outcomes in myeloma -Ieuan Walker
#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California
https://www.myelomasociety.org/
- Multiple locations
-International Study
- Arizona: Mayo Clinic Arizona
- California: University of California San Francisco
- Georgia: Emory University Atlanta
- Illinois: University of Chicago
- Missouri: Washington University School of Medicine Saint Louis
- Minnesota: Mayo Clinic Rochester Minnesota
- New Jersey: Hackensack University Medical Center
- New York: Memorial Sloan-Kettering Cancer Center New York
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New York: New York Presbyterian / Weill Cornell Medical College New York
- New York: NYU Langone Medical Center New York
- North Carolina: Levine Cancer Institute Charlotte
- Tennessee: Sarah Cannon Research Institute Nashville
- Texas: UT Southwestern Medical Center Dallas
- Texas: Baylor University Medical Center Dallas
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Connecticut
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Illinois
United States, Kansas
United States, Maryland
United States, Michigan
United States, Minnesota
United States, Mississippi
United States, Missouri
United States, Montana
United States, Nebraska
United States, New Hampshire
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Oregon
United States, Tennessee
United States, Texas
United States, Virginia
United States, Washington
United States, Wisconsin
Canada, Alberta
Canada, Ontario
Canada, Quebec
Europe
Spain